Table 4.
Variables Associated With Clustering in Individuals Initiating Antiretroviral Therapy Within El Salvador's Human Immunodeficiency Virus Genetic Network
| Variable | Clustering No. (%) |
Crude OR (95% CI) |
P Value | Adjusted OR (95% CI)a |
P Value |
|---|---|---|---|---|---|
| Gender | |||||
| Male (n = 160) | 33 (20.6) | 1.00 | 1.00 | ||
| Female (n = 43) | 6 (14.0) | 0.62 (.24–1.61) | .325 | 0.93 (.32–2.74) | .901 |
| Transgender (n = 6) | 0 (0.0) | … | … | ||
| Age category, y | |||||
| ≤25 (n = 51) | 16 (31.4) | 1.00 | 1.00 | ||
| 26–32 (n = 47) | 10 (21.3) | 0.59 (.23–1.49) | .261 | 0.59 (.21–1.66) | .320 |
| 33–40 (n = 55) | 5 (9.1) | 0.22 (.07–.69) | .004 | 0.23 (.07–.77) | .017 |
| >40 (n = 55) | 8 (14.6) | 0.37 (.14–.99) | .040 | 0.55 (.19–1.64) | .285 |
| Viral load category | |||||
| Quartile 1 (n = 51) | 10 (19.6) | 1.00 | 1.00 | ||
| Quartile 2 (n = 52) | 11 (21.2) | 1.10 (.42–2.89) | .846 | 1.25 (.43–3.61) | .675 |
| Quartile 3 (n = 51) | 4 (7.8) | 0.35 (.10–1.23) | .086 | 0.38 (.10–1.44) | .156 |
| Quartile 4 (n = 52) | 13 (25.0) | 1.27 (.53–3.50) | .513 | 2.03 (.69–5.97) | .197 |
| State of residence | |||||
| San Salvador (n = 95) | 12 (12.6) | 1.00 | 1.00 | ||
| Other (n = 114) | 27 (23.7) | 2.15 (1.01–4.56) | .042 | 1.74 (.75–4.05) | .196 |
| Any HIVDR | |||||
| No (n = 162) | 28 (17.3) | 1.00 | 1.00 | ||
| Yes (n = 47) | 11 (23.4) | 1.46 (.66–3.23) | .344 | 2.47 (.97–6.33) | .059 |
| Previous ARV exposure | |||||
| No (n = 162) | 37 (22.8) | 1.00 | 1.00 | ||
| Yes (n = 47) | 2 (4.3) | .15 (.03–.67) | .004 | 0.14 (.03–.65) | .013 |
Statistically significant associations (P < .05) are marked in bold.
Abbreviations: ARV, antiretroviral; CI, confidence interval; HIVDR, human immunodeficiency virus drug resistance; OR, odds ratio.
a
Logistic regression model including gender, age category, viral load, state of residence, presence of HIVDR, and previous ARV exposure. Number of observations in the model: 199. Missing data for age: 1, viral load: 3.